More thoughts on “How I Treat Cytopenias after CAR T-cell Therapy” - ScienceDirect ⁦@DrFredLocke⁩ and Dr Tim Olson ⁦@BloodJournal⁩ ⁦@NiraliShahMD⁩ ⁦@fabianaperna⁩

Retrospectively, we saw these same outcomes with more toxicity back when I did this as my PGY-1 research project at NMH. Excited to see this as an oral this #ASH22

⏰ #ASH22 LATE BREAKING ABSTRACT ANNOUNCEMENT! ⏰ It's a big year for post-transplant cyclophosphamide (PTCy) and @BMTCTN! The primary analysis of #BMTCTN1703 is here! https://t.co/8M6yACHe7m A thread 🧵/ @ASHClinicalNews @ASH_hematology

Huge shoutout to @MariLucenaBMT for spearheading this awesome initiative! Also to @DWRx and Tony Proli for their work on the committee!

📣 ICYMI, the ASTCT Pharmacy Education SIG had its very first (!!) Early Career Search Initiative Panel! It was such an honor to moderate this panel of influencial pharmacy leaders, including @KelleyCPharmD @lakenned93 @roddyjv & more! Catch it free here!

Ventured out to Connecticut for the 5th New England Hematologic Malignancies Symposium & so glad I did! Great speakers with spectacular presentations - looking forward to next year! @Dr_AmerZeidan terrific planning, thank you 👏🏽

A few years ago a mentally ill man threatened to kill me after his wife’s complex karyotype secondary AML relapsed post allogeneic transplant. The days until he was apprehended and admitted to an inpatient psychiatric institution were one of the scariest times of my life./1

What a treat! Listening to my former colleague and inspiration @jaltmanmd start off the leukemia sessions at @GreatDebatesCME! A captivating talk with excellent & compelling points 👏🏽#GDU2022 #leusm

No one: . . ID: why was it ordered?

If you ever have questions about what oral chemotherapy you can crush, make into solution, etc. this article is a MUST SAVE. Just used it for a quick reference to tretinoin via NG tube. Hats off to @CWagnerPharmD for summarizing all the lit. #oncopharm https://t.co/yHMQvaE274

Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence. Patients with t(11;14) have: - Lower CD38 - Lower CD138 - Higher PAX5 & CD79A - Higher BCL2/BCL2L1 ratio #mmsm https://t.co/dBc3Cco9ca

“G-CSF administered early post-transplant results in a two-fold increase in non-relapse mortality and a 10% absolute decrement in survival” - important educational considerations re: best HCT supportive care practices

Strong case made by ⁦@IreneGhobrial⁩ at #IMW21 #IMW2021 for screening early individuals at higher risk of developing #myeloma ⁦@PromiseStudy⁩ #mmsm

Outcome of Myeloma patients <40 years at diagnosis. N=214, 18% high-risk cytogenetics, 90% autoSCT; median PFS 41 months, median OS 14.5 years. MM dramatically shortens the survival of young patients despite a median OS of 14.5 years. #mmsm #bmtsm

Excellent outcomes in selected older #myeloma patients with Auto-HSCT. In this age group, I strongly prefer upfront over delayed transplant (irrespective of cytogenetic risk) as they may miss the opportunity of delayed transplant at relapse #mmsm #bmtsm

HLA-haploidentical vs MUD transplants with posttransplant cyclophosphamide-based prophylaxis. Mortality rates were higher with reduced-intensity regimens after haploidentical than with MUD transplantation #bmtsm @romeerizwan @CIBMTR

The accuracy.

A newer approach to lower-intensity threrapy for older pts with AML. Happy to share our group's work @DrHKantarjian @garciamanero @NitinJainMD @kanagalshamanna

N=118; median age 72yo - p53 mut = 30%. Of those: CR/CRi = 57%; 60 day mortality = 26%; dismal OS - as we have come to expect for p53 mutated AML - similarly projected outcomes using decitabine, with or without ven.

3 truths about MRD in #mmsm 1) MRD is prognostic 2) We do not know “yet” that altering treatment to achieve MRD negativity makes people live longer or better 3)Every single MRD meta-analysis compares good biology responders to bad biology non responders and is hence flawed.